Browse by author
Lookup NU author(s): Dr Timothy Hardy, Professor Fiona OakleyORCiD, Professor Quentin AnsteeORCiD, Professor Chris Day
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver dysfunction in the Western world and is increasing owing to its close association with obesity and insulin resistance. NAFLD represents a spectrum of liver disease that, in a minority of patients, can lead to progressive nonalcoholic steatohepatitis (NASH), fibrosis, and ultimately hepatocellular carcinoma and liver failure. NAFLD is a complex trait resulting from the interaction between environmental exposure and a susceptible polygenic background and comprising multiple independent modifiers of risk, such as the microbiome. The molecular mechanisms that combine to define the transition to NASH and progressive disease are complex, and consequently, no pharmacological therapy currently exists to treat NASH. A better understanding of the pathogenesis of NAFLD is critical if new treatments are to be discovered.
Author(s): Hardy T, Oakley F, Anstee QM, Day CP
Publication type: Review
Publication status: Published
Journal: Annual Review of Pathology: Mechanisms of Disease
Year: 2016
Volume: 11
Pages: 451-496
Online publication date: 03/03/2016
Acceptance date: 01/01/1900
ISSN (print): 1553-4006
Publisher: ANNUAL REVIEWS
URL: http://dx.doi.org/10.1146/annurev-pathol-012615-044224
DOI: 10.1146/annurev-pathol-012615-044224
